GEKKOVET-OY
17.6.2021 11:34:12 CEST | Business Wire | Press release
There are hundreds of different diseases and even more symptoms that can affect pets. Even a veterinarian cannot remember all of them without help. The new GekkoCompass application, recently launched by a Finnish company, suggests the most probable diagnosis and the appropriate treatment at the touch of a button to the veterinarian.
In treating their patients, veterinarians use numerous different sources to arrive at a diagnosis. Now, however, there is no longer a need for stacks of books or confusing notes. GekkoCompass creates a list of possible diagnoses in probability order, based on the patient’s symptoms, laboratory results, and other findings. After the diagnosis is selected, the appropriate treatments are suggested to the veterinarian. GekkoCompass provides support throughout the patient's treatment chain reducing the risk of human error at all stages. It does not forget things and preconceptions will not influence the diagnoses suggested.
GekkoCompass currently includes information for internal diseases of dogs and cats. With these alone there are nearly 25,000 different disease-symptom combinations. The content will grow to embrace new animal species as well as different fields of veterinary medicine. All this information is available to all veterinarians worldwide - regardless of the level of veterinary education or the country’s resources.
Johanna Majamaa, CEO of GekkoVet Oy, states: “The main idea behind this application’s development has been the desire to promote animal welfare worldwide. With GekkoCompass, the veterinarian will find diagnoses and recommended treatments faster and with greater confidence. At the same time, information is accumulated as veterinary medicine real world data (RWD). This is the first time ever when this data is automatically structured along the patient treatment path. PetCompass, a sister product that we have just launched, arose out of this same idea, but is intended for pet owners. We thought, why not provide professional-level information to animal owners as well and facilitate the flow of information between owners and veterinarians?”
Until now, pet owners have had to look for pet health information from a variety of sources, the reliability of which varies greatly. Now up-to-date information on the pet’s condition is easily available in one place through the PetCompass mobile app.
GekkoVet Oy is working with If P&C Insurance, which offers its dog and cat insurance customers the Premium version of the PetCompass application for 3 months free of charge. “During the corona pandemic, the number of new pet owners has grown sharply. We want to help, especially, the less experienced dog and cat owners by offering peace of mind in the different everyday situations that they and their pets find themselves in. The application provides a reliable and effortless way to discover the causes of a pet's symptoms and to easily get in touch with a veterinarian (or a remote veterinarian) if this is necessary,” says Heidi Elomaa, If's veterinarian and Product Manager for Animal Insurance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005381/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
